Stock comparison

BMYvsJNJ

Bristol-Myers Squibb CovsJohnson & Johnson. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BMY

Bristol-Myers Squibb Co

$59.02

+8.71%

Pharmaceuticals$117.4BNYSE

JNJ

Johnson & Johnson

$230.65

+9.01%

Pharmaceuticals$585.7BNYSE

60-day price, rebased to 100

BMY +8.73% · JNJ +1.29%

Round-by-round

BMY 3·JNJ 2· 1tie

EdgeBMY

Valuation upside

+2.90% vs -37.60% to DCF fair value

EdgeJNJ

Balance-sheet strength

Altman Z 2.20 vs 5.08

EdgeBMY

Fundamental quality

Piotroski 9.00 vs 4.00 (of 9)

Tie

Growth + margins

Rule-of-40 26.40 vs 26.60

EdgeBMY

60-day momentum

+8.73% vs +1.29% price return

EdgeJNJ

Market-cap liquidity

$117.4B vs $585.7B

Verdict

Across6categories,BMYtakes the edge with3wins to2 (and 1 tie). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBMYorJNJ

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.